Publications scientifiques

2614 PUBLICATIONS

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

ANNÉE2022

JOURNALCancer cell

PREMIER AUTEURLimagne E

TITREMEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.

ANNÉE2022

JOURNALClinical nuclear medicine

PREMIER AUTEURMairal E

TITREMultiparametric 18F-FDG and 68GA-DOTATOC PET Imaging in Bone Metastatic Meningioma Before Radionuclide Therapy: Assessment of Tumor Heterogeneity.

ANNÉE2022

JOURNALEuropean radiology

PREMIER AUTEURCazzato RL

TITREPercutaneous image-guided cryoablation of spinal metastases: over 10-year experience in two academic centers.

ANNÉE2022

JOURNALCancers

PREMIER AUTEURSani S

TITRETemozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.

ANNÉE2022

JOURNALJournal of biomolecular structure & dynamics

PREMIER AUTEUROubella A

TITRECytotoxic and apoptotic effects of some (R)-carvone-isoxazoline derivatives on human fibrosarcoma and carcinoma cells: experimental evaluation for cytotoxicity, molecular docking and molecular dynamics studies.

ANNÉE2022

JOURNALCancer chemotherapy and pharmacology

PREMIER AUTEURReda M

TITREOptimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

ANNÉE2022

JOURNALBMC surgery

PREMIER AUTEURGomes David M

TITRECytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.

ANNÉE2022

JOURNALAnnals of surgical oncology

PREMIER AUTEURPaquette B

TITRECytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.

ANNÉE2022

JOURNALExperimental dermatology

PREMIER AUTEURZanella A

TITREPD-L1 in circulating exosomes of Merkel cell carcinoma.

ANNÉE2022

JOURNALBritish journal of cancer

PREMIER AUTEURYchou M

TITREChemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques